<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Metapneumovirus infection &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/metapneumovirus-infection/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Fri, 12 Jun 2026 11:16:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Metapneumovirus infection &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older</title>
		<link>https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ivx-a12-vaccine-for-preventing-respiratory-infections-in-adults-aged-60-and-older/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 15:05:19 +0000</pubDate>
				<category><![CDATA[Vaccine]]></category>
		<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ivx-a12-vaccine-for-preventing-respiratory-infections-in-adults-aged-60-and-older/</guid>

					<description><![CDATA[This clinical trial is focused on studying two respiratory diseases: Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV). These viruses can cause lung infections, especially in older adults. The study will test a new vaccine called IVX-A12, which is designed to protect against both RSV and hMPV. The vaccine is given as a solution for [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial is focused on studying two respiratory diseases: <b>Respiratory Syncytial Virus (RSV)</b> and <b>Human Metapneumovirus (hMPV)</b>. These viruses can cause lung infections, especially in older adults. The study will test a new vaccine called <b>IVX-A12</b>, which is designed to protect against both RSV and hMPV. The vaccine is given as a solution for injection into the muscle.</p>
<p>The purpose of the study is to see how well the IVX-A12 vaccine works in preventing lung infections caused by RSV and hMPV in adults aged 60 and older. Participants in the study will receive either the IVX-A12 vaccine or a placebo, which is a substance that looks like the vaccine but does not contain the active ingredients. The study will monitor participants over a period of time to check for any signs of these infections and to assess the safety of the vaccine.</p>
<p>Participants will be followed through different seasons to observe the occurrence of infections. The study aims to gather information on how effective the vaccine is in preventing these infections and to ensure it is safe for use in older adults. This research is important for developing new ways to protect against these common respiratory viruses.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
